

William C Weldon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/298780/publications.pdf>

Version: 2024-02-01

52
papers

1,216
citations

393982

19
h-index

395343

33
g-index

53
all docs

53
docs citations

53
times ranked

1272
citing authors

#	ARTICLE	IF	CITATIONS
1	The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. <i>Lancet, The</i> , 2019, 394, 148-158.	6.3	123
2	Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. <i>Vaccine</i> , 2015, 33, 4683-4690.	1.7	98
3	Standardized Methods for Detection of Poliovirus Antibodies. <i>Methods in Molecular Biology</i> , 2016, 1387, 145-176.	0.4	97
4	The novel adjuvant dmlT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. <i>Vaccine</i> , 2015, 33, 1909-1915.	1.7	69
5	Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes. <i>Plant Biotechnology Journal</i> , 2016, 14, 2190-2200.	4.1	69
6	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. <i>Lancet, The</i> , 2021, 397, 27-38.	6.3	53
7	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. <i>Lancet, The</i> , 2021, 397, 39-50.	6.3	49
8	Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3611-3621.	1.4	41
9	Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. <i>Scientific Reports</i> , 2016, 6, 22094.	1.6	41
10	Neutralizing Antibody against Enterovirus D68 in Children and Adults before 2014 Outbreak, Kansas City, Missouri, USA1. <i>Emerging Infectious Diseases</i> , 2019, 25, 585-588.	2.0	39
11	Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. <i>Vaccine</i> , 2014, 32, 4938-4944.	1.7	38
12	High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. <i>Scientific Reports</i> , 2017, 7, 12644.	1.6	36
13	Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 217, 371-380.	1.9	32
14	Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan. <i>Journal of Infectious Diseases</i> , 2018, 217, 443-450.	1.9	30
15	Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. <i>Lancet, The</i> , 2019, 393, 2624-2634.	6.3	30
16	Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 898-904.	4.6	23
17	Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 559-568.	4.6	22
18	Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae). <i>Antiviral Research</i> , 2018, 149, 75-77.	1.9	21

#	ARTICLE	IF	CITATIONS
19	Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 218, 1876-1882.	1.9	21
20	Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine. <i>Vaccine</i> , 2020, 38, 1652-1660.	1.7	20
21	Seroprevalence of Poliovirus Antibodies in the United States Population, 2009–2010. <i>BMC Public Health</i> , 2016, 16, 721.	1.2	16
22	Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan. <i>Vaccine</i> , 2017, 35, 3209-3214.	1.7	15
23	Polio immunity and the impact of mass immunization campaigns in the Democratic Republic of the Congo. <i>Vaccine</i> , 2017, 35, 5693-5699.	1.7	15
24	A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania. <i>Journal of Infectious Diseases</i> , 2021, 223, 119-127.	1.9	14
25	Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures. <i>Biologicals</i> , 2018, 53, 30-38.	0.5	13
26	Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants. <i>Clinical Infectious Diseases</i> , 2018, 67, S42-S50.	2.9	12
27	The effect of diarrheal disease on bivalent oral polio vaccine (bOPV) immune response in infants in Nepal. <i>Vaccine</i> , 2016, 34, 2519-2526.	1.7	11
28	Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. <i>Vaccine</i> , 2017, 35, 7283-7291.	1.7	11
29	Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan. <i>Vaccine</i> , 2018, 36, 1766-1771.	1.7	10
30	Rapid Disappearance of Poliovirus Type 2 (PV2) Immunity in Young Children Following Withdrawal of Oral PV2-Containing Vaccine in Vietnam. <i>Journal of Infectious Diseases</i> , 2019, 220, 386-391.	1.9	10
31	Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses. <i>Clinical Infectious Diseases</i> , 2018, 67, S66-S77.	2.9	9
32	Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. <i>The Lancet Global Health</i> , 2022, 10, e257-e268.	2.9	9
33	Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species. <i>Vaccine</i> , 2019, 37, 698-704.	1.7	8
34	Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients. <i>Vaccine</i> , 2020, 38, 3042-3049.	1.7	8
35	Effect of booster doses of poliovirus vaccine in previously vaccinated children, Clinical Trial Results 2013. <i>Vaccine</i> , 2016, 34, 3803-3809.	1.7	7
36	Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012–2013. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 776-783.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017. <i>Vaccine</i> , 2018, 36, 1921-1924.	1.7	7
38	Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka. <i>Journal of Infectious Diseases</i> , 2019, 219, 1887-1892.	1.9	7
39	Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
40	Seroprevalence of Anti-polio Antibodies in Children From Polio High-risk Areas of Pakistan. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, e230-e236.	1.1	6
41	Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa. <i>Vaccine</i> , 2018, 36, 1027-1031.	1.7	6
42	Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar. <i>Heliyon</i> , 2018, 4, e00563.	1.4	6
43	Cytokine biomarkers associated with clinical cases of acute flaccid myelitis. <i>Journal of Clinical Virology</i> , 2020, 131, 104591.	1.6	4
44	Assessment of immunity to polio among Rohingya children in Coxâ€™s Bazar, Bangladesh, 2018: A cross-sectional survey. <i>PLoS Medicine</i> , 2020, 17, e1003070.	3.9	4
45	Poliovirus immunity among children under five years-old in accessible areas of Afghanistan, 2013. <i>Vaccine</i> , 2019, 37, 1577-1583.	1.7	3
46	Estimating population immunity to poliovirus in Jordanâ€™s high-risk areas. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 548-553.	1.4	3
47	Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan. <i>Vaccine: X</i> , 2020, 5, 100067.	0.9	3
48	Neutralizing Ljungan virus antibodies in children with newly diagnosed type 1 diabetes. <i>Journal of General Virology</i> , 2021, 102, .	1.3	3
49	Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria. <i>PLoS ONE</i> , 2017, 12, e0185284.	1.1	3
50	Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria. <i>Clinical Infectious Diseases</i> , 2018, 67, S103-S109.	2.9	2
51	Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children. <i>Journal of Infectious Diseases</i> , 2020, , .	1.9	1
52	Estimating population immunity to poliovirus in Lebanon: Results from a seroprevalence survey, 2016. <i>Vaccine</i> , 2020, 38, 4846-4852.	1.7	0